The potential of artemisinins as anti-obesity agents via modulating the immune system
Copyright © 2020. Published by Elsevier Inc..
Artemisinin and its derivatives are the most effective antimalarial drugs. Besides anti-malarial activity, artemisinin and its derivatives have displayed wide-spectrum bioactivities such as anti-parasite, anti-tumor, and anti-obesity effects. Obesity is an epidemic worldwide which is a big threat to human health, but there are only a few approved anti-obesity drugs in the world. Also, these drugs are efficient to limited patients partly because their safety and efficacy are questioned. Anti-inflammatory therapies may be valuable in obesity treatment since growing evidence shows chronic metabolic inflammation is implicated in metabolic disease pathogenesis. As artemisinin and its derivatives display effective anti-inflammatory and immunoregulatory properties with less toxicity, it provides an insight for novel drug development in obesity therapeutic strategies via immune-regulatory mechanisms. In this review, the potential of artemisinin and its derivatives to treat various metabolic diseases such as obesity and diabetes is discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:216 |
|---|---|
| Enthalten in: |
Pharmacology & therapeutics - 216(2020) vom: 01. Dez., Seite 107696 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shen, Shengnan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 31.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pharmthera.2020.107696 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315924918 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315924918 | ||
| 003 | DE-627 | ||
| 005 | 20231225155951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pharmthera.2020.107696 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM315924918 | ||
| 035 | |a (NLM)33022301 | ||
| 035 | |a (PII)S0163-7258(20)30226-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shen, Shengnan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The potential of artemisinins as anti-obesity agents via modulating the immune system |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 31.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Inc. | ||
| 520 | |a Artemisinin and its derivatives are the most effective antimalarial drugs. Besides anti-malarial activity, artemisinin and its derivatives have displayed wide-spectrum bioactivities such as anti-parasite, anti-tumor, and anti-obesity effects. Obesity is an epidemic worldwide which is a big threat to human health, but there are only a few approved anti-obesity drugs in the world. Also, these drugs are efficient to limited patients partly because their safety and efficacy are questioned. Anti-inflammatory therapies may be valuable in obesity treatment since growing evidence shows chronic metabolic inflammation is implicated in metabolic disease pathogenesis. As artemisinin and its derivatives display effective anti-inflammatory and immunoregulatory properties with less toxicity, it provides an insight for novel drug development in obesity therapeutic strategies via immune-regulatory mechanisms. In this review, the potential of artemisinin and its derivatives to treat various metabolic diseases such as obesity and diabetes is discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-inflammatory | |
| 650 | 4 | |a Artemisinin | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Multi-target | |
| 650 | 4 | |a Obesity | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Anti-Obesity Agents |2 NLM | |
| 650 | 7 | |a Artemisinins |2 NLM | |
| 650 | 7 | |a Inflammation Mediators |2 NLM | |
| 700 | 1 | |a Liao, Qiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Lyu, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Yin-Kwan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jigang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacology & therapeutics |d 1981 |g 216(2020) vom: 01. Dez., Seite 107696 |w (DE-627)NLM000442402 |x 1879-016X |7 nnns |
| 773 | 1 | 8 | |g volume:216 |g year:2020 |g day:01 |g month:12 |g pages:107696 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pharmthera.2020.107696 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 216 |j 2020 |b 01 |c 12 |h 107696 | ||